2. Academic Validation
  3. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow

In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow

  • Environ Toxicol Pharmacol. 2017 Jan;49:58-64. doi: 10.1016/j.etap.2016.11.014.
Guoping Wang 1,  Guobo Shen 1,  Tao Yin 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu 610041, PR China.
  • 2 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu 610041, PR China. Electronic address: [email protected].
PMID: 27915123 DOI: 10.1016/j.etap.2016.11.014
Abstract

Deferoxamine (DFO), an iron chelator, is commonly used to remove excess iron from the body. DFO has also been demonstrated to have anti-tumor effect. However, there is no available report on the effect of deferoxamine on mesenchymal stromal cells (MSCs). In this study, we first isolated tumor-associated MSCs (TAMSCs) from EG-7 tumors, which were positive for CD29, CD44, CD73, CD90 and CD105. Ex vivo cultured stem cells derived from tumor and bone marrow compartment were exposed to DFO. We demonstrated that DFO had growth-arresting and apoptosis-inducing effect on TAMSCs and bone marrow MSCs (BMMSCs). DFO also influenced the expression pattern of adhesion molecule VCAM-1 on both TAMSCs and BMMSCs. Notwithstanding its widespread use, our results here warrants caution in the application of DFO, and also highlights the need for careful evaluation of the bone marrow compartment in patients receiving DFO treatment.

Keywords

Deferoxamine; ICAM-1; Mesenchymal stromal cells; VCAM-1.

Figures
Products